$Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy$

Invasive fungal disease is rare in patients with relapsed/refractory multiple myeloma treated with BCMA CAR T-cell therapy

Saved in:

Bibliographic Details
Main Authors:	Jessica S. Little, Angelica Medina Pena, E. Bridget Kim, Andrew J. Yee, Omar Nadeem, Shonali Midha, Adam S. Sperling, Nikhil C. Munshi, Noopur Raje, Matthew J. Frigault, Diana D. Cirstea, Sarah P. Hammond
Format:	Article
Language:	English
Published:	Elsevier 2025-08-01
Series:	Blood Advances
Online Access:	http://www.sciencedirect.com/science/article/pii/S2473952925003647
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma
by: Joshua N. Gustine, et al.
Published: (2025-06-01)

Bridging intensity is associated with impaired hematopoietic recovery after BCMA CAR-T therapy for multiple myeloma
by: Jan H. Frenking, et al.
Published: (2025-08-01)

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
by: Yuhan Yan, et al.
Published: (2024-11-01)

Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
by: Yok-Lam Kwong, et al.
Published: (2025-03-01)

Key predictors of long-term outcomes in BCMA-targeted CAR-T therapy for relapsed/refractory multiple myeloma
by: Ning An, et al.
Published: (2025-05-01)

BCMA CAR-T therapy as salvage therapy in patients with plasmablastic myeloma
by: Chengwei Jin, et al.
Published: (2025-12-01)

The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
by: Adrian Schmidt
Published: (2023-10-01)

BCMA-directed CAR T-cell therapy in patients with multiple myeloma and CNS involvement
by: Mahmoud R. Gaballa, et al.
Published: (2025-03-01)

Case Report: BCMA-targeting CAR T-cell therapy induces complete and durable remission in relapsed extramedullary plasmablastic multiple myeloma
by: Lili Zhou, et al.
Published: (2025-05-01)

Safety and efficacy of BCMA CAR-T <i>vs.</i> bispecific antibodies in patients with relapsed multiple myeloma: a systematic review and meta-analysis
by: Hayley Vandenboom, et al.
Published: (2025-08-01)

Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
by: Brandon Tedder, et al.
Published: (2025-07-01)

Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma
by: Benjamin Adegbite, et al.
Published: (2025-08-01)

Nivolumab to restore T-cell fitness in CAR-T refractory multiple myeloma
by: Johannes M. Waldschmidt, et al.
Published: (2025-03-01)

Clinical impact of [18F]FDG-PET/CT in ARI0002h treatment, a CAR-T against BCMA for relapsed/refractory multiple myeloma
by: Inés Zugasti, et al.
Published: (2025-02-01)

Engineering anti-BCMA CAR T cells for enhancing myeloma killing efficacy via apoptosis regulation
by: Thomas Kimman, et al.
Published: (2025-05-01)

Radiation therapy to manage isolated relapse after chimeric antigen receptor T-cell therapy in multiple myeloma
by: Surbhi Srinivas, et al.
Published: (2025-06-01)

Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma
by: Lina Zhang, et al.
Published: (2021-01-01)

Case Report: Summary of multiple CAR-T expansions in anti-BCMA/GPRC5D bispecific CAR-T cell therapy for multiple myeloma
by: Liya Wei, et al.
Published: (2025-06-01)

Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival
by: Zachary M. Avigan, et al.
Published: (2025-01-01)

CAR-T cell therapy in older adults with relapsed/refractory LBCL: benefits and challenges
by: Matthew J Frigault, et al.
Published: (2025-06-01)

BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial
by: Hao Yao, et al.
Published: (2025-05-01)

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma
by: Xu Yang, et al.
Published: (2024-12-01)

Correction: BCMA/GPRC5D bispecific CAR T-cell therapy for relapsed/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial
by: Hao Yao, et al.
Published: (2025-06-01)

EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2024-10-01)

THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT
by: Anuj Mahindra, et al.
Published: (2010-05-01)

Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium
by: Danai Dima, et al.
Published: (2025-06-01)

Targeting BCMA in multiple myeloma: designs, challenges, and future directions
by: Yi Hu, et al.
Published: (2025-02-01)

Early daratumumab therapy improves renal outcomes in newly diagnosed patients with myeloma admitted with kidney injury
by: E. Bridget Kim, et al.
Published: (2025-07-01)

Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myeloma
by: Djordje Atanackovic, et al.
Published: (2025-07-01)

Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
by: Andrew J. Yee, et al.
Published: (2025-03-01)

The Rapidly Evolving Treatment Landscape in Newly Diagnosed Multiple Myeloma: Current Status and Future Directions
by: Yuxin Liu, et al.
Published: (2024-10-01)

The Evolving Role of Alkylating Agents in Multiple Myeloma: From the Past and Present to Next-Generation Peptide Drug Conjugates
by: Yuxin Liu, et al.
Published: (2025-06-01)

Prognostic significance of PET/CT for CAR T cell therapy in relapsed/refractory multiple myeloma
by: Patrick Born, et al.
Published: (2025-06-01)

Use of CAR-T cells for the treatment of relapsed and refractory multiple myeloma: a systematic review
by: Satchie Sakamoto, et al.
Published: (2024-01-01)

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematology
by: Alina Ershova, et al.
Published: (2025-07-01)

The incidence and clinical significance of monoclonal and oligoclonal protein bands in multiple myeloma patients after BCMA–CAR‐T cell therapy: A retrospective study based on LEGEND‐2
by: Rui Liu, et al.
Published: (2024-11-01)

BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting
by: Huijian Zheng, et al.
Published: (2025-03-01)

The impact of antibiotic use on outcomes of relapsed/refractory multiple myeloma patients treated with CAR-T therapy
by: Lingling Yin, et al.
Published: (2025-04-01)

TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model
by: Aina Oliver-Caldes, et al.
Published: (2025-12-01)

Potent anti‐tumor response by targeting B cell maturation antigen (BCMA) in a mouse model of multiple myeloma
by: Felix Oden, et al.
Published: (2015-08-01)